June 19, 2019

Pfizer's CEO Makes Large Strategic Play in Oncology
by Patricia Van Arnum, DCAT Editorial Director
Albert Bourla, who became CEO of Pfizer in January, has made his first large-scale deal as CEO: a pending $11.4-billion acquisition of Array BioPharma, which specializes in small-molecule cancer drugs. How does the move fit into the company’s strategy, and what may be on the horizon? Read More

Pharma Industry Weighs in on Continuous Manufacturing
by Patricia Van Arnum, DCAT Editorial Director

The pharma industry is providing
feedback on the FDA’s draft guidance on continuous manufacturing, with GSK, Eli Lilly, AstraZeneca, J&J, the Association
for Accessible Medicines, CEFIC’s
Active Pharmaceutical Ingredients Committee, and IPEC-America among those offering input. What did they have
to say? Read More
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .